Hologic has a Zacks Rank of #2 (Buy), while Edwards Lifesciences has a Zacks Rank of #3 (Hold) right now. This means that HOLX's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in. HOLX currently has a forward P/E ratio of 18.26, while EW has a forward P/E of 31.82. We also note that HOLX has a PEG ratio of 2.48. This metric is used similarly to the famous P/ ...